ASCO Gastrointestinal Cancer Symposium

African-American men with mCRPC may derive greater overall survival benefit from treatment with newer chemotherapies than Caucasian men.

In this interview, we spoke with John J. Coen, MD, a radiation oncologist who presented results at the 2018 Genitourinary Cancers Symposium of a phase II study exploring two different radiation-plus-chemotherapy combination strategies in patients undergoing bladder surgery for their tumors.

Pazopanib was not associated with prolonged progression-free survival compared with temsirolimus among patients with advanced clear-cell renal cell carcinoma, but a subgroup analysis of intermediate-risk patients offered some reason for optimism.

Adjuvant platinum-based chemotherapy is associated with delayed metastasis among patients diagnosed with upper-tract urothelial carcinoma, according to findings from the phase III POUT trial.

Adjuvant therapy with sunitinib after nephrectomy was associated with increased mortality among older women with renal cell carcinoma, according to a subgroup analysis of data from the ASSURE trial.

Combining axitinib and pembrolizumab is “safe and tolerable” among patients with previously untreated advanced renal cell carcinoma, with 73% of patients responding, according to findings from an open-label, phase Ib trial.

Fewer patients diagnosed with testicular cancer were uninsured, and fewer were diagnosed with late-stage disease, following the Affordable Care Act’s Medicaid enrollment expansion.

Researchers reported promising safety data from an ongoing phase Ib/II clinical trial for SM-88, an investigational combination therapy that might one day offer an alternative to androgen deprivation therapy for men with recurrent, nonmetastatic prostate cancer.

Enzalutamide resulted in a 71% reduction in metastatic disease risk among men with castration-resistant prostate cancer and rapid prostate-specific antigen doubling time, according to the first interim analysis of data from the phase III PROSPER trial. 

Researchers are developing a prognostic hypoxia gene signature for patients with localized prostate cancer that could predict biochemical failure and metastasis.

A newly developed clinical model can predict overall survival for patients diagnosed with advanced bladder cancer who are treated with atezolizumab.

Adding docetaxel chemotherapy to frontline hormone therapy improves quality of life and may reduce the need for subsequent treatment, according to an analysis from the STAMPEDE trial.

Adding atezolizumab and bevacizumab to standard care was tolerable and slowed tumor growth in patients with previously untreated clear-cell or sarcomatoid-histology metastatic renal cell carcinoma when compared to sunitinib, according to findings from a phase III study.

Apalutamide was well-tolerated and associated with delayed metastasis in men with high-risk castration-resistant prostate cancer that has become refractory to conventional hormone therapy, according to an early interim analysis of the phase III SPARTAN clinical trial.

Active surveillance prior to initiating targeted therapy might benefit patients with metastatic renal cell carcinoma, since it delays therapy and toxicities.

Dacomitinib induction therapy has shown activity in HPV-negative, locally advanced or metastatic penile squamous cell carcinoma.

Computer-assisted tumor objective response evaluations for patients with metastatic renal cell carcinoma can save time and reduce errors.

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

Genomic subtyping of muscle-invasive bladder cancer could inform decisions on when best to use neoadjuvant cisplatin-based chemotherapy, according to a retrospective, non-randomized study.

A single cycle of adjuvant bleomycin, etoposide, and cisplatin (BEP) chemotherapy might reduce recurrence rates for nonseminomatous or combined germ cell tumors of the testis.

Intravesical rAd-IFNα/Syn3 showed promising response rates, a tolerable treatment schedule, and acceptable toxicity among patients with high-grade, nonmuscle-invasive bladder cancer, refractory or relapsed after bacillus Calmette-Guérin therapy.

This video examines the results of a study that looked at the prognostic value of androgen receptor full-length detection using a CTC-based mRNA assay in metastatic castration-resistant prostate cancer patients starting treatment with AR-targeted agents.

Pembrolizumab is associated with longer overall survival and fewer treatment-related toxicities vs chemotherapy for patients with advanced urothelial carcinoma.

The Decipher prostate cancer gene-expression classifier can predict patients’ risk of metastasis and prostate cancer-specific mortality using biopsy specimens prior to radical prostatectomy or radiotherapy plus androgen deprivation.

In this interview we discuss the latest clinical news in urothelial carcinoma, what we’ve learned about the biology of these tumors, and how treatment of this disease has evolved.

Immunotherapy offers durable responses lasting more than 6 months after treatment discontinuation for some patients with metastatic renal cell carcinoma.

Antibiotics administered less than a month before initiation of immunotherapies for patients with advanced kidney cancer might impair tumor control, according to a retrospective analysis.

“Liquid biopsy” analyses of circulating tumor DNA from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer, and might point the way for development of new targeted treatments.